SHL Group reaches major milestone of 3,000 employees
Within just two years of reaching a milestone of 2,500 employees, SHL Group has rapidly reached 3,000 employees worldwide. This increase is reflective of a steady yet rapid growth in the injectable drug delivery market and SHL’s effective commitment, productivity, and management.
A global leader in the design and manufacturing of autoinjectors and pen injectors, SHL offers innovative designs, robust manufacturing capabilities, a lean supply chain, strong partnerships, and more. With offices and manufacturing facilities located in Taiwan, Sweden, the US and China, SHL aims for the highest product and service quality, better brand recognition, and building of business values for employees and customers.
Over the years, SHL has continuously invested in R&D and manufacturing capabilities, and currently houses more than 180 high precision molding machines selected from leading brands worldwide. With expert engineers operating such state-of-the-art equipment, SHL has been able to meet increasing customer demands for response time, quality, and capacity.
“SHL is committed to developing innovative devices and providing exceptional customer service, thus we never hesitate when it comes to further investments and expansions if it means providing better quality and capacity for our customers,” said Roger Samuelsson, President and CEO of SHL Group. “We have been extending and expanding our services and production sites over the years, and will continue to do so to accommodate future needs. Reaching 3,000 employees in such a short time is a true milestone for us and we look forward to bringing more leading-edge technology to market in such areas as autoinjectors and pen injectors, inhalers, connectivity, and much more.”
At present, SHL works with 80% of the world’s top 25 pharmaceutical companies. Its sites expand across Sweden, the US, Taiwan, and China. Currently there are nine major production sites in Taiwan.
